GLP-1 Market
LLY $1415.51 ▲ +0.3% NVO $40.70 ▼ -1.6% PFE $28.98 ▼ -0.8% VKTX $29.74 ▲ +2.6% KLRA $14.34 ▲ +4.7% GPCR $22.32 ▲ +4.3% RHHBY $61.32 ▲ +3.3%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Verapamil /24 Hours

Company
Assistance Publique - Hôpitaux de Paris
Mechanism
Mechanism not yet reported
Route
Oral
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Nov 10, 2026

Trial details
  • Not yet recruiting NCT NCT07880769

    Verapamil In Preclinical Type 1 Diabetes

    Not yet reported, Not yet reported Assistance Publique - Hôpitaux de Paris 50 participants Est. completion 2031-03 1 site Stand-alone
    Other conditions: Type 1 Diabetes
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Verapamil /24 Hours, Verapamil 120 Mg/24 Hours Oral Capsule, Extended Release

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.